PA
WGS icon

PharVision Advisers’s GeneDx Holdings WGS Stock Holding History

PharVision Advisers’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,879
Closed -$202K – 1033
2025
Q3 		$202K Buy
+1,879
New +$205K 0.11% 511
2025
Q1 		– Sell
-3,910
Closed -$301K – 530
2024
Q4 		$301K Buy
+3,910
New +$273K 0.25% 152

Other funds holding WGS

CM
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PharVision Advisers's WGS Position: Q4 2025 in Review

PharVision Advisers sold out of GeneDx Holdings (WGS) in Q4 2025, closing a stake of 1,879 shares — an estimated $202K sold.

PharVision Advisers first reported a position in WGS in Q4 2024 and held it in 2 quarters. The position peaked at $301K in Q4 2024. 286 funds tracked by Wall St. Rank hold WGS as of Q4 2025.

  • PharVision Advisers reported no remaining GeneDx Holdings position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 1,879 GeneDx Holdings shares in Q4 2025, an estimated $202K.
  • PharVision Advisers first reported a position in GeneDx Holdings in Q4 2024 and held it in 2 quarters.
  • PharVision Advisers's GeneDx Holdings position peaked at $301K in Q4 2024.
  • 286 funds tracked by Wall St. Rank held GeneDx Holdings as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.